MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Buys $69,770.58 in Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Stan Smith purchased 57,189 shares of MAIA Biotechnology stock in a transaction on Monday, December 22nd. The shares were acquired at an average cost of $1.22 per share, for a total transaction of $69,770.58. Following the purchase, the director owned 1,421,478 shares in the company, valued at approximately $1,734,203.16. This trade represents a 4.19% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Stan Smith also recently made the following trade(s):

• On Friday, December 5th, Stan Smith acquired 13,740 shares of MAIA Biotechnology stock. The stock was acquired at an average cost of $1.20 per share, with a total value of $16,488.00.
• On Tuesday, November 25th, Stan Smith bought 15,000 shares of MAIA Biotechnology stock. The stock was acquired at an average price of $0.98 per share, with a total value of $14,700.00.
• On Monday, November 24th, Stan Smith purchased 10,000 shares of MAIA Biotechnology stock. The stock was acquired at an average cost of $0.99 per share, for a total transaction of $9,900.00.
• On Wednesday, October 1st, Stan Smith purchased 19,230 shares of MAIA Biotechnology stock. The stock was acquired at an average price of $1.30 per share, with a total value of $24,999.00.

MAIA Biotechnology Price Performance

Shares of MAIA stock opened at $1.48 on Friday. The firm’s 50-day simple moving average is $1.21 and its 200-day simple moving average is $1.50. MAIA Biotechnology, Inc. has a 1-year low of $0.87 and a 1-year high of $2.74. The firm has a market cap of $54.80 million and a P/E ratio of -2.03.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its earnings results on Friday, November 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.08). Analysts expect that MAIA Biotechnology, Inc. will post -1.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MAIA. Centric Wealth Management raised its holdings in shares of MAIA Biotechnology by 740.2% in the 2nd quarter. Centric Wealth Management now owns 573,398 shares of the company’s stock worth $1,032,000 after purchasing an additional 505,150 shares during the period. Jane Street Group LLC acquired a new stake in MAIA Biotechnology during the 2nd quarter worth approximately $52,000. Marshall Wace LLP purchased a new position in MAIA Biotechnology in the second quarter valued at approximately $29,000. Centerpoint Advisory Group acquired a new position in MAIA Biotechnology during the second quarter valued at approximately $28,000. Finally, Geode Capital Management LLC grew its stake in MAIA Biotechnology by 3.6% during the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after buying an additional 7,746 shares during the period. Institutional investors and hedge funds own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.